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Oral carcinoma after hematopoietic stem cell transplantation - a
new classification based on a literature review over 30 years
Abstract
BACKGROUND: Patients undergoing hematopoietic stem cell transplantation (HSCT) have a higher
risk of developing secondary solid tumors, in particular squamous cell carcinoma, because of several
risk factors, including full-body irradiation (TBI), chemotherapy, and chronic graft versus host disease
(GVHD). Based on the review presented here, a classification of oral changes is suggested in order to
provide a tool to detect high-risk patients. Methods and Results The literature over the last 30 years was
reviewed for development of malignoma of the oral cavity after HSCT. Overall, 64 cases were found. In
16 out of 30 cases, the tongue was the primary location, followed by the salivary gland (10 out of 30);
56.4% appeared in a latency time of 5 to 9 years after HSCT. In 76.6%, GVHD was noticed before the
occurrence of oral malignancy. Premalignant changes of the oral mucosa were mucositis, xerostomia,
and lichenoid changes, developing into erosive form. CONCLUSION: All physicians involved in the
treatment of post-HSCT patients should be aware of the increased risk, even after 5 years from the
development of oral malignancy, in particular when oral graft versus host changes are visible. In order
to develop evidence management and to detect and offer adequate therapy as early as possible in this
patient group, multicenter studies, involving oncologists and head and neck surgeons, should be
established.
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Abstract
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) have a higher
risk of developing secondary solid tumors, in particular squamous cell carcinoma, because of
several risk factors, including full-body irradiation (TBI), chemotherapy, and chronic graft versus
host disease (GVHD). Based on the review presented here, a classification of oral changes is
suggested in order to provide a tool to detect high-risk patients.
Methods and Results: The literature over the last 30 years was reviewed for development of
malignoma of the oral cavity after HSCT. Overall, 64 cases were found. In 16 out of 30 cases, the
tongue was the primary location, followed by the salivary gland (10 out of 30); 56.4% appeared in
a latency time of 5 to 9 years after HSCT. In 76.6%, GVHD was noticed before the occurrence of
oral malignancy. Premalignant changes of the oral mucosa were mucositis, xerostomia, and
lichenoid changes, developing into erosive form.
Conclusion: All physicians involved in the treatment of post-HSCT patients should be aware of
the increased risk, even after 5 years from the development of oral malignancy, in particular when
oral graft versus host changes are visible. In order to develop evidence based management,
screening and offer adequate therapy as early as possible in this patient group, multicenter studies,
involving oncologists and head and neck surgeons, should be established.
Introduction
Allogenic hematopoietic stem cell transplantation
(HSCT) has been increasingly used for therapy in recent
years, leading to improvements in the survival rate.
Despite this improvement, HSCT can also lead to long-
term complications like the development of malignant
neoplasm, which can be divided into three main sub-
groups: hematologic malignancy, lymphoproliferative
disorder, and solid tumor. The first two are more com-
mon, developing after the transplantation, while the last
one seems to be rare, and it occurs after both HSCT and
GVHD [1] (Fig. 1).
In GVHD, a common complication in patients who have
been treated with HSCT, immunocompetent donor T cells
attack the genetically disparate host cells [2]. Billingham
[3] described in 1966 three conditions for the develop-
ment of GVHD. First, the graft must contain immunolog-
ically competent cells. Second, the recipient must reveal
expression of tissue antigens that are not present in the
donor; and finally, the recipient must be incapable of
rejecting the transplanted cells. Nowadays, it is well
accepted that these immunologically competent cells are
donor T cells that react against histocompatibility anti-
gens. Therefore, the degree of HLA mismatch is one of the
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sex mismatch, patient age, donor parity, choice of graft
source, pre-infusion graft modulations, and T cells deple-
tion [4]. In the pathogenesis process, tissue damage occurs
first, caused by radiation/chemotherapy; second, donor T
cells recognize host antigens from the damaged tissue as
foreign, and finally, they are activated [5].
By definition, acute GVHD develops within 100 days,
whereas the chronic form develops after 100 days [6]. The
latter form is described in up to 40% of long-term survi-
vors after HSCT [7].
The secondary solid tumors after GVHD include squa-
mous cell carcinoma (SCC), melanoma, glioblastoma,
and sarcoma [8]. Carcinomas have been reported in the
lungs, liver, skin, parotid gland, and oral mucosa.
In general, risk factors for development of oral squamous
cell carcinoma in patients without HSCT are regular
tobacco and alcohol consumption, HPV, insufficient
mouth hygiene, immune deficiency, and the presence of
lichen planus as a premalignant lesion. The last is also
described as an oral manifestation of chronic GVH.
Because of the rare appearance of oral carcinoma in
patients who have undergone HSCT, the purpose of the
present paper is to review published cases of this entity
from the last 30 years, with and without GVHD, in order
to evaluate potential risk and prognosis factors for the
development of oral carcinomas. Furthermore, until now
no classification has been available for changes in the oral
mucosa after HSCT. Therefore, a clinical classification will
be presented with emphasis on these risk factors.
Materials and methods
For this literature review, a literature search was done
using the Internet-based PubMed (National Library of
Medicine and National Institute of Health, USA), limiting
the search to reports of clinical trials, review articles, meta-
analyses, and case reports published in English and Ger-
man medical and dental journals from 1978–2008.
Patients with Fanconi's anemia (FA) were excluded
because they have an inborn susceptibility to cancer. The
hazard rate for cancer in FA patients was reported to be
2% per year by the age of 24 years with a cumulative inci-
dence of 29% by the age of 48 years (Alter et al. 2003).
Results
Between 1978 and 2008, 5 case reports and 12 studies
involving oral carcinoma in combination with HSCT were
published, including 64 cases in all (Table S1; Additional
File 1) [9-24]. In 40 cases the gender distribution was not
specified; the male-to-female distribution was 19:5 in all
other cases. In 16 of 30 specified original diseases, SAA
(severe aplastic anemia) was predominant (Fig. 2). In 30
patients the localization of the oral malignant neoplasm
was not specified; in all other cases the tongue (16 out of
30) was the most common location, followed by the sub-
mandibular gland (8 out of 30) (Fig. 3). Concerning the
distribution of latency time between HSCT and the
appearance of oral malignancy, 39 cases were specified;
the main group was between 5 and 9 years (56.4%), fol-
lowed by the group for 10 years or more (23.1%) (Fig. 4).
In 76.6% GVHD was observed before the occurrence of
oral malignancy (Fig. 5). Over the 5 case reports, 9 cases
were presented with oral GVHD; the oral changes are pre-
sented in Figure 6.
Development of oral SCC after HSCT or GVHDFigure 1
Development of oral SCC after HSCT or GVHD.
Distribution of primary diagnosisFigure 2
Distribution of primary diagnosis.Page 2 of 6
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total body irradiation (TBI) was performed in 17 cases.
Discussion
The incidence of secondary neoplasm for cancer of the
oral cavity, esophagus, or thyroid gland in patients with
previous HSCT is 4 to 7 times that of the general popula-
tion [16,24,25]. Several risk factors for occurrence of solid
tumors after HSCT have been discussed in the literature,
including total-body radiation [26-28], chemotherapy
[15], male gender [11], virus [8,29], young age [16],
chronic GVHD [24,28], and prior immunosuppressive
therapy [11].
The present gender distribution of 19:5 supports the
observation by Gluckman [11] and Bhatia [28] that males
have a higher risk than females for development of sec-
ondary oral malignancy, though males are only slightly
more likely than females to receive HSCT (62% to 56%)
[11,15,28].
Even though some authors have proposed total-body irra-
diation as an independent risk factor for solid tumors [25-
27], others [15] do not support this. In the present study
for oral malignancy, in only 29 cases was the pretreatment
specified, and of those, 19 had total-body radiation (Fig.
7). In addition, Hojo et al. (1999) [30] proposed that
cyclosporine can promote cancer progression by a direct
cellular effect that is independent of its effect on the host's
immune cells. This statement was supported by Kolb et al.
[15], who described immunosuppressive treatment, in
particular cyclosporine and azathioprine, as the most sig-
nificant risk factor for secondary malignant neoplasm. In
the current study data from only 10 patients, information
on cyclosporine and/or azathiorprine are available; thus a
statement concerning their influence on the development
of oral cancer and comparison to patients under immuno-
suppression because of organ transplants is not possible
due to lack of data.
Distribution of localizationFigure 3
Distribution of localization.
Latency time (years) between HSCT and oral malignancyFigure 4
Latency time (years) between HSCT and oral malig-
nancy.
Distribution of patients with previous GVHDFigure 5
Distribution of patients with previous GVHD.
Distribution of premalignant oral conditionsFigure 6
Distribution of premalignant oral conditions.Page 3 of 6
(page number not for citation purposes)
Head & Neck Oncology 2009, 1:29 http://www.headandneckoncology.org/content/1/1/29Kolb (1999) [15] described a risk for a malignant neo-
plasm of 3.5% at 10 years after HSCT and 11.5% at 15
years, with the overall incidence of malignant tumors
being about 5-fold greater than that in an age-and-sex-
matched population and more than 10-fold greater for
cancer of the oral cavity, esophagus, or thyroid gland. In
the current overview, the latency time between HSCT and
occurrence of oral malignancy in the group between 5 and
9 years was increased. Instances in the group of more than
10 years would likely be higher, because GVHD contrib-
utes to significant post-HCT morbidity and mortality. In
the present study 47 patients had already revealed the
occurrence of the oral cancer GVHD. In most studies the
differentiation concerning the specification of the oral
form of GVHD is missing. But in the 9 case reports in all
cases, an oral involvement of GVHD was described. This
oral form is characterized pathohistologically by mucosal
hyperkeratosis, erythema, atrophy, inflammation, pseu-
domembranous ulceration [5], fibrosis, and salivary
gland disorder [31]. Probably one reason for the rare data
in the studies could be the difficulty of the differential
diagnosis of oral GVHD like neutropenia-associated
mucositis, recrudescent HSV, or cytomegalovirus stomati-
tis [32].
Controversy still surrounds the etiology of oral SSC in-
patients with GVHD. Lichenoid changes of the oral
mucosa in combination with oral GVHD were present in
6 of the 9 single case reports. Because lichen has a malig-
nant potential, the malignant transformation in GVHD is
probably based on the development of oral lichen. Under
both conditions (without previous HSCT and after
HSCT), basal cells are the prime target of destruction, and
T lymphocytes become cytotoxic for basal keratinocytes
[33]. For the onset of OLP, an immunological cause
related to coinfection and administration of different
medication is discussed [34]. Therefore, the question
arises whether total-body radiation with application of
immunosuppressive agencies like cyclosporine/azathio-
prine can lead to the development of lichen in patients
after HSCT. Bradfort (1990) [35] presented 2 cases after
organ transplantation and treatment with azathioprine
that developed a squamous cell carcinoma, but in one
case the patient had an ethanol and nicotine (100 py)
consumption; thus the risk of developing an oral squa-
mous cell carcinoma was already considerable.
Apart from the fact that the most common localization in
the oral cavity was the tongue (6/35), the number of sali-
vary gland malignoma (10/35) is striking: from those 10
cases, only 5 of the tumors have been verified, and all 5
were mucoepidermoid carcinomas. Some authors com-
pare the clinical features of GVHD with those of other
autoimmune connective tissue disorders, like progressive
systemic sclerosis and Sjörgen's syndrome [36]; in both
those diseases, hyposalivation is described. Nakamura
[37] shows that periductal lymphocytic infiltratin is typi-
cal in Sjorgens's syndrome but not in GVHD patients,
while Nicolatou-Galltis (2000) [38] describes mild peri-
ductal monocytic infiltration in GVHD patients.
The described xerostomia as a cause of oral GVHD was
mentioned in 2 of the 9 single case reports. Mucoepder-
moid and squamous cell carcinoma in salivary gland
tumors originate from the excretory duct, but in the cur-
rent literature, there has been no investigation concerning
the histopathological changes in these excretory ducts as a
cause of oral GVHD.
Concerning therapy for GVHD several strategies have
been discussed, but because of missing data, evidence for
management is still missing. The most common seems to
be cyclosporine in combination with corticosteroids for
regression of T cell proliferation; one of the disadvantages
after long-term use can be an increased incidence of squa-
mous cell carcinoma [39]. Second, Tacrolimus has an
overall response rate of 20%. Third, Sirolimus is described
as having a reduced risk of gingival overgrowth [39]. But
in all single case reports, patients had previously revealed
an oral manifestation of GVHD and nevertheless devel-
oped, particularly in the oral cavity, a malignant neo-
plasm. In the literature no data are available on how many
patients with a treated oral GVHD did not develop an oral
malignancy.
Table 1: Classification of clinical intraoral changes after 
hematopoietic stem cell transplantation
Grade Clinical intraoral features
0 No involvement
1 Erythema and/or hyposalivation
2 Lichenoid appearance
3 Ulceration, tumor
Distritubtion of pretreatmentFigure 7
Distritubtion of pretreatment.Page 4 of 6
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from big studies summarizing all secondary tumors after
HSCT, thus resulting in a lack of specific data for tumors
of the oral cavity. Most of the big studies provided infor-
mation independent of the tumor localization, so precise
data concerning, e.g., oral manifestation of GVHD were
not available.
Very few studies described the follow-up [18], but the
squamous cell carcinoma of the oral cavity after HSCT
seems to be very aggressive [18,23], and therefore early
detection is extremely important. Therefore, based on the
descriptions of intraoral premalignant conditions and the
occurrence of oral GVHD in the current available studies,
a classification (Table 1) is suggested in order to provide a
tool to detect high-risk patients. In all cases other risk fac-
tors, such as smoking or regular alcohol use, should be
avoided. Besides the systemic therapy in cases of GVHD,
in cases of erythema/mucositis particular attention should
be paid also to optimization of oral hygiene and mouth
rinsing with cyclosporine, along with a strict follow-up.
Lichenoid appearance must be controlled regularly in
order not to miss erosive changes that need to be biop-
sied.
Conclusion
All physicians treating patients post-HSCT, even after 5
years or more, should be aware of the increased risk of
developing oral malignancy, in particular when oral graft
versus host changes are visible. Many questions concern-
ing the etiology are still not solved; therefore, multicenter
studies that involve oncologists and head and neck sur-
geons should be established in order to investigate the
pathogenesis and also to detect as early as possible
patients at high risk for oral malignancy in order to offer
adequate therapy.
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